MARCELLA WHEELER: Open Payments
NPI 1487600227 · BEAUMONT, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$498 in 22 payments from 9 companies in 2025. Trend: 2023 $434 · 2024 $547 · 2025 $498
Food & beverage: $498
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $192 |
| GlaxoSmithKline, LLC. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| ABBVIE INC. | 2 | $48 |
| Lilly USA, LLC | 2 | $46 |
| Madrigal Pharmaceuticals | 1 | $33 |
| PFIZER INC. | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $14 |
Products named: FARXIGA, CAPLYTA, BREZTRI, VRAYLAR, JARDIANCE, TRELEGY ELLIPTA, AIRSUPRA, REZDIFFRA.
Industry payments across TX — which companies pay providers there.
